CHRSCoherus Oncology, Inc.

CHRS Stock Price, Valuation & Chart | Coherus Oncology, Inc.

Compare

$1.420+0.05 (+3.65%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology CHRS intrinsic value CHRS calculated fair value vs price

Overview Financials Dividends Ratios

CHRS Historical price chart

CHRS Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization219.39M

PE Ratio-1.28

EPS-1.11

Trading Volume620.90K

Today's High/Low1.43/1.35

Dividend Yield0.00

52 Week High/Low2.62/1.09

Shares Outstanding154.50M

CHRS Financial Statement

CHRS Analyst ratings

CHRS Analysis & performance metrics

CHRS Company profile

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops…

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human…

CHRS Management team

Name

Position

Michael Chen

Senior Vice President of Commercial Analytics & Trade

Dennis M. LanfearCEO

Chairman, President & Chief Executive Officer

Jodi Sievers

Vice President of Investor Relations & Corporate Communications

Andy Rittenberg

Executive Vice President of General Counsel

Richard L. Hameister

Chief Technical Officer

Scott Saywell

Executive Vice President of Corporate Development

Rosh Dias M.D., MRCP

Chief Medical Officer

Rebecca Sunshine

Chief Human Resources Officer

Name

Position

Michael Chen

Senior Vice President of Commercial Analytics & Trade

Dennis M. LanfearCEO

Chairman, President & Chief Executive Officer

Jodi Sievers

Vice President of Investor Relations & Corporate Communications

Andy Rittenberg

Executive Vice President of General Counsel

Richard L. Hameister

Chief Technical Officer

Scott Saywell

Executive Vice President of Corporate Development

Rosh Dias M.D., MRCP

Chief Medical Officer

Rebecca Sunshine

Chief Human Resources Officer

Management Team

Michael Chen

Senior Vice President of Commercial Analytics & Trade

Dennis M. LanfearCEO

Chairman, President & Chief Executive Officer

Jodi Sievers

Vice President of Investor Relations & Corporate Communications

Andy Rittenberg

Executive Vice President of General Counsel

Richard L. Hameister

Chief Technical Officer

Scott Saywell

Executive Vice President of Corporate Development

Rosh Dias M.D., MRCP

Chief Medical Officer

Rebecca Sunshine

Chief Human Resources Officer

Management

Michael Chen

Senior Vice President of Commercial Analytics & Trade

Dennis M. LanfearCEO

Chairman, President & Chief Executive Officer

Jodi Sievers

Vice President of Investor Relations & Corporate Communications

Andy Rittenberg

Executive Vice President of General Counsel

Richard L. Hameister

Chief Technical Officer

Scott Saywell

Executive Vice President of Corporate Development

Rosh Dias M.D., MRCP

Chief Medical Officer

Rebecca Sunshine

Chief Human Resources Officer

Total 8 executives

CHRS Frequently asked questions

What is Coherus Oncology, Inc. (CHRS) Stock Price?

Current stock price of Coherus Oncology, Inc. (CHRS) stock is $1.420. The stock price is +3.65% higher in the session. The intraday range can be seen from this page. Volume of Coherus Oncology, Inc. (CHRS) stock is 620.90K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Coherus Oncology, Inc. (CHRS) stock price going up or down today?

The stock price of Coherus Oncology, Inc. (CHRS) can change with earnings, company news, and overall market sentiment. Coherus Oncology, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Coherus Oncology, Inc. stock expensive at its current price?

Whether Coherus Oncology, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for CHRS on this page is -1.28. EPS on this page is -1.11. Compare those figures with peers and growth expectations before deciding if the current Coherus Oncology, Inc. price is justified.

How has the stock price of Coherus Oncology, Inc. (CHRS) performed historically?

Historical performance for Coherus Oncology, Inc. (CHRS) is shown on the price chart on this page. Review multi-period moves alongside volume to see how CHRS reacted to past earnings and market events.

Should I buy Coherus Oncology, Inc. (CHRS) stock, at this price?

Buying Coherus Oncology, Inc. (CHRS) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.